Representatives of 30 nations were yesterday to meet to seek ways to save fast-depleting tuna stocks in the Indian Ocean as demand in Asia and the West soars for sushi and canned fish.
The Indian Ocean Tuna Commission (IOTC), which groups coastal countries from Australia to Kenya plus major fishing region the EU, was convening virtually over five days to debate yellowfin tuna quotas.
Environmentalists have said the warm-water species is at risk of depletion as overfishing compounds other threats from climate change and pollution.
There is corporate concern, too: British supermarkets Tesco and Co-op, and Belgian retailer Colruyt last year pledged to stop buying Indian Ocean yellowfin unless the UN-mandated commission adopts a plan to rebuild stocks.
The International Union for Conservation of Nature has for nearly a decade had the species on its “red list.”
Yet the total global catch has risen by about one-third, to nearly 450,000 tonnes annually, according to the London-based Blue Marine Foundation advocacy group.
It has estimated that yellowfin tuna stocks could “collapse” — meaning they would go beyond the minimum size needed for recovery — within the next five years if the catch is not cut.
French and Spanish fishing fleets take the majority of fish, using industrial methods such as “purse seine” with huge nets that often net juvenile yellowfin yet to begin reproducing.
Coastal nations want to limit Europe’s distant-water fleets.
Kenya and Sri Lanka, for example, want more curbs on devices such as fish aggregators: floating objects that attract tuna and other species toward nets.
“They are the visitors,” said Will McCallum, Head of Oceans at environmental group Greenpeace UK, of the European fleets. “They are fishing at a far larger capacity than anybody else, and it’s not an equitable state of affairs.”
The Maldives wants the yellowfin catch to be cut by 15 percent from 2015 levels, when IOTC scientists first agreed they were being overfished.
The IOTC had last year recommended cutting the catch by 20 percent from 2014 levels, but rowed back in January, saying that was distorted by projections from the 2018 stock assessment.
Given that a new stock assessment would not be ready until the end of this year, the commission might postpone new measures, the Blue Marine Foundation said.
“For a stock that is at risk of collapse, this delay could prove catastrophic,” it said in a statement.
The EU has proposed a total catch reduction from nearly 438,000 tonnes in 2019 to about 380,000.
Demand for yellowfin is booming as its light meat is widely used for canned fish and in sushi in North America, Europe and Asia. The global yellowfin market in 2018 was worth US$15.8 billion, the second-highest value of the seven tuna species, according to a report by the world’s largest canned tuna company, Thai Union Group.
McCallum said the overfishing issue had stalled during the COVID-19 pandemic and drastic action was needed now to avoid irrecoverable damage to the species.
The COVID-19 variant discovered in South Africa can “break through” Pfizer-BioNTech’s COVID-19 vaccine to some extent, a real-world data study released on Saturday found, although its prevalence in the country is low and the research has not been peer reviewed. The study in Israel compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated people with the disease. It matched age and gender, among other characteristics. The South African variant, B.1.351, was found to make up about 1 percent of all the COVID-19
RARE ADMISSION: A top Chinese expert was the first to publicly address the efficacy of the nation’s vaccines as it aims to inoculate 40 percent of its population by June China is considering mixing different COVID-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert told a conference in Chengdu on Saturday. Authorities have to “consider ways to solve the issue that efficacy rates of existing vaccines are not high,” Chinese media outlet The Paper reported, citing Chinese Center for Disease Control and Prevention Director Gao Fu (高福). His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country’s vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world. China
The Australian government yesterday said that it had decided against buying the single-dose Johnson & Johnson (J&J) COVID-19 vaccine and identified a second case of a rare blood clot likely linked to the AstraZeneca shot. The Australian government had been in talks with the New Jersey-based pharmaceutical giant, which had asked the Australian Therapeutic Goods Administration for provisional registration. However, Australian Minister of Health Greg Hunt ruled out a J&J contract, because its vaccine was similar to the AstraZeneca product, which Australia had already contracted for 53.8 million doses. Hunt said the government was following the advice of Australia’s scientific and technical advisory
The Indonesian government has said it is satisfied with the effectiveness of the Chinese COVID-19 vaccine it has been using, after China’s top disease control official said that current vaccines offer low protection against the novel coronavirus. Siti Nadia Tarmizi, a spokesperson for Indonesia’s COVID-19 vaccine program, on Monday said the WHO had found that the Chinese vaccines had met requirements by being more than 50 percent effective. Clinical trials in Indonesia for the vaccine from Chinese drugmaker Sinovac showed that it was 65 percent effective, she said. “It means ... the ability to form antibodies in our bodies is still very